Market Overview:
The global induced myeloid leukemia cell differentiation protein Mcl 1 market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of leukemia, rising investments in R&D for novel therapies, and growing demand for targeted therapies. However, the high cost of treatment and lack of awareness about leukemia are some factors that are likely to restrain the growth of this market during the forecast period. Based on type, the global induced myeloid leukemia cell differentiation protein Mcl 1 market is segmented into AZD-5991, FL-118, S-64315, UMI-77 and others. Based on application, it is segmented into ovarian cancer prostate cancer hematological tumor non Hodgkin lymphoma and others.
Product Definition:
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 is a protein that helps induce myeloid leukemia cell differentiation. It is important for regulating the differentiation of leukemic cells into mature blood cells, and may play a role in treating leukemia.
AZD-5991:
It is a novel oral immunomodulator, which works by targeting the Bcr-Abl gene. It was discovered and developed by AbbVie Inc., a U.S.-based pharmaceutical company in collaboration with Daiichi Sankyo Company Ltd., Japan in 2019.
FL-118:
FL-118 is a monoclonal antibody that targets the immunoglobulin G4 (IgG4) subunit of the Induced Myeloid Leukemia (IML) cell differentiation protein Mcl 1. It has been tested in multiple clinical trials for treatment against IML and it has shown to have an overall response rate of approximately 50% with no major side effects.
Application Insights:
Induced myeloid leukemia cell differentiation protein mcl-1 is used for the treatment of various cancers such as prostate cancer, non-hodgkin lymphoma, and ovarian cancer. The application of induced myeloid leukemia cell differentiation protein mcl-1 in the treatment of prostate cancer dominated the overall market in terms of revenue share in 2017 owing to increasing incidence rates and awareness about available treatments.
The use of this product for treating Non-Hodgkin Lymphoma (NHL) is expected to witness lucrative growth over the forecast period due to rising incidence rates and availability of advanced therapies.
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the presence of key players, such as Pfizer Inc.; Celgene Corporation; and AbbVie, Inc., which are engaged in extensive R&D for development of novel drugs targeting Mcl-1. In addition, high incidence rate of cancer coupled with favorable government initiatives for drug development is expected to boost regional growth over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to increasing number of clinical trials being conducted in this region and rising awareness about early diagnosis & treatment methods for various cancers including leukemia.
Growth Factors:
- Increasing incidence of leukemia
- Growing demand for novel therapies for leukemia treatment
- Rising public and private investments in cancer research
- Technological advancements in induced myeloid leukemia cell differentiation protein Mcl 1 therapy development
- Growing number of clinical trials evaluating the efficacy of induced myeloid leukemia cell differentiation protein Mcl 1 therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report
By Type
AZD-5991, FL-118, S-64315, UMI-77, Others
By Application
Ovarian Cancer, Prostate Cancer, Hemotological Tumor, Non-Hodgkin Lymphoma, Others
By Companies
AbbVie Inc, Amgen Inc, AstraZeneca Plc, Complix NV, Les Laboratoires Servier SAS, Takeda Pharmaceutical Co Ltd, Warp Drive Bio Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
226
Number of Tables & Figures
159
Customization Available
Yes, the report can be customized as per your need.
Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Report Segments:
The global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 market is segmented on the basis of:
Types
AZD-5991, FL-118, S-64315, UMI-77, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Cancer, Prostate Cancer, Hemotological Tumor, Non-Hodgkin Lymphoma, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie Inc
- Amgen Inc
- AstraZeneca Plc
- Complix NV
- Les Laboratoires Servier SAS
- Takeda Pharmaceutical Co Ltd
- Warp Drive Bio Inc
Highlights of The Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AZD-5991
- FL-118
- S-64315
- UMI-77
- Others
- By Application:
- Ovarian Cancer
- Prostate Cancer
- Hemotological Tumor
- Non-Hodgkin Lymphoma
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Induced myeloid leukemia cell differentiation protein Mcl 1 is a protein that is found in the blood and bone marrow. It helps to control the growth of leukemia cells.
Some of the major players in the induced myeloid leukemia cell differentiation protein mcl 1 market are AbbVie Inc, Amgen Inc, AstraZeneca Plc, Complix NV, Les Laboratoires Servier SAS, Takeda Pharmaceutical Co Ltd, Warp Drive Bio Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Size & Forecast, 2020-2028 4.5.1 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Size and Y-o-Y Growth 4.5.2 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 AZD-5991
5.2.2 FL-118
5.2.3 S-64315
5.2.4 UMI-77
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Ovarian Cancer
6.2.2 Prostate Cancer
6.2.3 Hemotological Tumor
6.2.4 Non-Hodgkin Lymphoma
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 AZD-5991
9.6.2 FL-118
9.6.3 S-64315
9.6.4 UMI-77
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Ovarian Cancer
9.10.2 Prostate Cancer
9.10.3 Hemotological Tumor
9.10.4 Non-Hodgkin Lymphoma
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 AZD-5991
10.6.2 FL-118
10.6.3 S-64315
10.6.4 UMI-77
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Ovarian Cancer
10.10.2 Prostate Cancer
10.10.3 Hemotological Tumor
10.10.4 Non-Hodgkin Lymphoma
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 AZD-5991
11.6.2 FL-118
11.6.3 S-64315
11.6.4 UMI-77
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Ovarian Cancer
11.10.2 Prostate Cancer
11.10.3 Hemotological Tumor
11.10.4 Non-Hodgkin Lymphoma
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 AZD-5991
12.6.2 FL-118
12.6.3 S-64315
12.6.4 UMI-77
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Ovarian Cancer
12.10.2 Prostate Cancer
12.10.3 Hemotological Tumor
12.10.4 Non-Hodgkin Lymphoma
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 AZD-5991
13.6.2 FL-118
13.6.3 S-64315
13.6.4 UMI-77
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Ovarian Cancer
13.10.2 Prostate Cancer
13.10.3 Hemotological Tumor
13.10.4 Non-Hodgkin Lymphoma
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market: Competitive Dashboard
14.2 Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie Inc
14.3.2 Amgen Inc
14.3.3 AstraZeneca Plc
14.3.4 Complix NV
14.3.5 Les Laboratoires Servier SAS
14.3.6 Takeda Pharmaceutical Co Ltd
14.3.7 Warp Drive Bio Inc